This post is about drug companies raising prices, but it will not be about Martin Shkreli and his company. (I’ve decided, by the way, to stop referring to it by name, because it annoys me no end that it’s such a blatant attempt to borrow the name recognition of a great man). No, I’ll just mention that despite his public statements, Shkreli doesn’t seem to have actually announced any new price for Daraprim, so his business model continues to have a lot more in common with an extortion racket than a legitimate drug company.
Read Full Article »
